55197-36-9

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-aminomethyl-phenyl)-propionic acid is used as an anti-inflammatory agent for the treatment of rheumatoid arthritis, osteoarthritis, and other musculoskeletal conditions. It helps to reduce pain, inflammation, and fever by blocking the production of certain natural substances in the body.
Used in Pain Management:
3-(4-aminomethyl-phenyl)-propionic acid is used as a pain reliever for various conditions, including headaches, menstrual cramps, and dental pain. It works by blocking the production of prostaglandins, which are responsible for pain and inflammation.
Used in Topical Application:
3-(4-aminomethyl-phenyl)-propionic acid is used as a topical solution for the treatment of localized pain and inflammation. The topical application allows for targeted relief and reduces the risk of systemic side effects.

Upstream product

• 16642-94-7 (E)-4-cyanocinnamic acid 
• 501-52-0 3-Phenylpropionic acid 
• 56703-33-4 β-(p-chloromethylphenyl)propionic acid 

Downstream Products

• 919528-86-2 3-(4-{[(fluoren-9-ylmethoxy)carbonylamino]-methyl}phenyl)propanoic acid 
• 1173158-26-3 3-{4-[(prop-2-enyloxycarbonylamino)methyl]phenyl}propanoic acid 
• 1173158-31-0 N-{[4-(3-hydroxypropyl)phenyl]methyl}prop-2-enyloxycarboxamide 
• 1173158-36-5 C₂₂H₂₂N₂O₅ 
• 1173156-17-6 2-{[2-({[N-({4-[3-((2R)-2-amino-4-phenylbutanoylaminooxy)propyl]phenyl}methyl)carbamoyl]methyl}{2-[bis(carboxymethyl)amino]ethyl}amino)ethyl](carboxymethyl)amino}acetic acid trifluoroacetic acid salt 
• 1173158-46-7 C₅₅H₈₈N₆O₁₃ 
• 1173158-44-5 (2R)-N-{3-[4-(aminomethyl)phenyl]propoxy}-2-[(tert-butoxy)carbonylamino]-4-phenylbutanamide trifluoroacetic acid salt 
• 1173158-45-6 C₂₉H₃₉N₃O₆ 
• 1173156-15-4 2-{[2-({[N-({4-[3-((2R)-2-amino-3-indol-3-ylpropanoylaminooxy)propyl]phenyl}methyl)carbamoyl]methyl}{2-[bis(carboxymethyl)amino]ethyl}amino)ethyl](carboxymethyl)amino}acetic acid trifluoroacetic acid salt 
• 1173158-42-3 C₅₆H₈₇N₇O₁₃ 
• 1173158-39-8 (2R)-N-{3-[4-(aminomethyl)phenyl]propoxy}-2-[(tert-butoxy)carbonylamino]-3-indol-3-ylpropanamide trifluoroacetic acid salt 
• 1173158-41-2 C₃₀H₃₈N₄O₆ 
• 1173158-33-2 N-({4-[3-(aminooxy)propyl]phenyl}methyl)prop-2-enyloxycarboxamide hydrochloric acid salt 

Relevant academic research and scientific papers

N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

N-alkoxyamide conjugates as imaging agents

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

HYDRAZIDE CONJUGATES AS IMAGING AGENTS

The present disclosure is directed to diagnostic agents. More specifically, the disclosure is directed to compounds, diagnostic agents, compositions, and kits for detecting and/or imaging and/or monitoring a pathological disorder associated with coronary plaque, carotid plaque, aortic plaque, plaque of the arterial vessel, aneurism, vasculitis, and other diseases of the arterial wall. In addition, the disclosure is directed to methods of detecting and/or imaging and/or monitoring changes in the arterial wall, including expansive and constrictive remodeling, total vessel wall area, internal lumen size, and exterior artery perimeter.

Synthesis of isosteres of p-amidinophenylpyruvic acid. Inhibitors of trypsin thrombin, and pancreatic kallikrein.

A series of amino acids, amidino acids, and amidino esters was synthesized and the compounds were evaluated for their inhibitory activity against bovine trypsin, bovine thrombin, and porcine pancreatic kallikrein and as anticoagulants. Among these compounds, ethyl 4-amidino-2-iodophenoxyacetate was found to be the most effective inhibitor of the enzymes in question, with a potency (Ki = 3.16 x 10-6 M vs. trypsin; Ki = 4.8 x 10-5 M vs. thrombin) similar to that of p-amidinophenylpyruvic acid (Ki = 6.0 x 10-6 M vs. trypsin; Ki = 2.0 x 10-5 M vs. thrombin). Ethyl 4-amidino-2-iodophenoxyacetate was also found to be the most effective in blocking the clotting activity of plasma, as indicated by significant prolongation of the partial thromboplastin time. This paper reports the synthetic methods, the enzyme inhibitory activity, and the structure-activity relationships observed.